RETA Annual CFF
$1.49 M
-$7.65 M-83.75%
31 December 2022
Summary:
As of February 5, 2025, RETA annual cash flow from financing activities is $1.49 million, with the most recent change of -$7.65 million (-83.75%) on December 31, 2022. During the last 3 years, it has fallen by -$578.87 million (-99.74%).RETA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RETA Quarterly CFF
$76.78 M
+$63.70 M+486.89%
30 June 2023
Summary:
As of February 5, 2025, RETA quarterly cash flow from financing activities is $76.78 million, with the most recent change of +$63.70 million (+486.89%) on June 30, 2023. Over the past year, it has increased by +$76.24 million (+14091.68%).RETA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RETA TTM CFF
$90.61 M
+$76.24 M+530.41%
30 June 2023
Summary:
As of February 5, 2025, RETA TTM cash flow from financing activities is $90.61 million, with the most recent change of +$76.24 million (+530.41%) on June 30, 2023. Over the past year, it has increased by +$89.37 million (+7189.54%).RETA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RETA Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -83.8% | +10000.0% | +7189.5% |
| 3 y3 years | -99.7% | -57.9% | -88.0% |
| 5 y5 years | -98.8% | +31.8% | -84.4% |
RETA Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -99.7% | -86.6% | -88.2% |
Reata Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $76.78 M(+486.9%) | $90.61 M(+530.4%) |
| Mar 2023 | - | $13.08 M(+4066.2%) | $14.37 M(+867.9%) |
| Dec 2022 | $1.49 M(-83.7%) | $314.00 K(-28.0%) | $1.49 M(+10.7%) |
| Sept 2022 | - | $436.00 K(-19.4%) | $1.34 M(+8.0%) |
| June 2022 | - | $541.00 K(+178.9%) | $1.24 M(-73.3%) |
| Mar 2022 | - | $194.00 K(+13.5%) | $4.65 M(-49.1%) |
| Dec 2021 | $9.14 M(-98.1%) | $171.00 K(-49.3%) | $9.14 M(-96.9%) |
| Sept 2021 | - | $337.00 K(-91.5%) | $294.38 M(-2.6%) |
| June 2021 | - | $3.95 M(-15.5%) | $302.14 M(-37.1%) |
| Mar 2021 | - | $4.68 M(-98.4%) | $480.35 M(+0.7%) |
| Dec 2020 | $477.09 M(-17.8%) | $285.42 M(+3427.1%) | $477.09 M(-37.7%) |
| Sept 2020 | - | $8.09 M(-95.6%) | $765.48 M(+1.0%) |
| June 2020 | - | $182.16 M(>+9900.0%) | $757.75 M(+31.4%) |
| Mar 2020 | - | $1.42 M(-99.8%) | $576.62 M(-0.6%) |
| Dec 2019 | $580.36 M(+98.4%) | $573.80 M(>+9900.0%) | $580.36 M(+8231.3%) |
| Sept 2019 | - | $363.00 K(-64.9%) | $6.97 M(-97.1%) |
| June 2019 | - | $1.03 M(-80.0%) | $240.07 M(-19.2%) |
| Mar 2019 | - | $5.16 M(+1155.0%) | $297.30 M(+1.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $292.47 M(+127.3%) | $411.00 K(-99.8%) | $292.47 M(+0.1%) |
| Sept 2018 | - | $233.47 M(+300.7%) | $292.11 M(+74.7%) |
| June 2018 | - | $58.26 M(>+9900.0%) | $167.25 M(+53.5%) |
| Mar 2018 | - | $329.00 K(+585.4%) | $108.94 M(-15.3%) |
| Dec 2017 | $128.65 M(+106.4%) | $48.00 K(-100.0%) | $128.65 M(-0.2%) |
| Sept 2017 | - | $108.61 M(<-9900.0%) | $128.87 M(+545.9%) |
| June 2017 | - | -$43.00 K(-100.2%) | $19.95 M(-76.1%) |
| Mar 2017 | - | $20.04 M(+7432.3%) | $83.31 M(+33.7%) |
| Dec 2016 | $62.32 M(-7263.4%) | $266.00 K(-186.4%) | $62.32 M(+1.2%) |
| Sept 2016 | - | -$308.00 K(-100.5%) | $61.56 M(+0.1%) |
| June 2016 | - | $63.32 M(-6723.4%) | $61.52 M(-3525.6%) |
| Mar 2016 | - | -$956.00 K(+92.4%) | -$1.80 M(+106.4%) |
| Dec 2015 | -$870.00 K(<-9900.0%) | -$497.00 K(+44.9%) | -$870.00 K(+133.2%) |
| Sept 2015 | - | -$343.00 K(<-9900.0%) | -$373.00 K(+1143.3%) |
| June 2015 | - | $0.00(-100.0%) | -$30.00 K(0.0%) |
| Mar 2015 | - | -$30.00 K | -$30.00 K |
| Dec 2014 | $1000.00(-99.9%) | - | - |
| Dec 2013 | $1.65 M | - | - |
FAQ
- What is Reata Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Reata Pharmaceuticals?
- What is Reata Pharmaceuticals annual CFF year-on-year change?
- What is Reata Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Reata Pharmaceuticals?
- What is Reata Pharmaceuticals quarterly CFF year-on-year change?
- What is Reata Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Reata Pharmaceuticals?
- What is Reata Pharmaceuticals TTM CFF year-on-year change?
What is Reata Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of RETA is $1.49 M
What is the all time high annual CFF for Reata Pharmaceuticals?
Reata Pharmaceuticals all-time high annual cash flow from financing activities is $580.36 M
What is Reata Pharmaceuticals annual CFF year-on-year change?
Over the past year, RETA annual cash flow from financing activities has changed by -$7.65 M (-83.75%)
What is Reata Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of RETA is $76.78 M
What is the all time high quarterly CFF for Reata Pharmaceuticals?
Reata Pharmaceuticals all-time high quarterly cash flow from financing activities is $573.80 M
What is Reata Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, RETA quarterly cash flow from financing activities has changed by +$76.24 M (+14091.68%)
What is Reata Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of RETA is $90.61 M
What is the all time high TTM CFF for Reata Pharmaceuticals?
Reata Pharmaceuticals all-time high TTM cash flow from financing activities is $765.48 M
What is Reata Pharmaceuticals TTM CFF year-on-year change?
Over the past year, RETA TTM cash flow from financing activities has changed by +$89.37 M (+7189.54%)